24/7 Customer Assistance
24/7 Assistance with the best medical care at your service
Call us for any question
+91 90858 83067BLOCK-B, PH-1, Sushant Lok Phase I, Gurugram, Haryana 122001
IndiaOffice Hour: 09:00am - 09:00pm
info@medigocare.comPeritoneal cancer treatment at 85% lower cost than USA â coordinated by MediGoCare.
HIPEC cytoreductive surgery in India â cost, eligibility and survival rates for peritoneal cancer patients
If you or someone you love has just been told the cancer has spread to the abdominal lining â the peritoneum â the next few weeks can feel overwhelming. Words like peritoneal carcinomatosis and cytoreductive surgery can seem confusing and frightening. But there is a treatment that has changed outcomes for thousands of patients worldwide. It's called HIPEC surgery. And India is now one of the most experienced and most affordable destinations to get it done.
We've coordinated HIPEC treatment journeys for patients from the UK, Nigeria, Bangladesh, Oman, and across the Gulf. In our experience at MediGoCare, the patients who do best are the ones who ask the right questions early. This guide covers everything â the procedure, the cost, who qualifies, which hospitals to consider, when HIPEC is not appropriate, and exactly how we help you get there. For broader context on cancer treatment options in India, start with our Complete Cancer Treatment India Guide for International Patients.
HIPEC stands for Hyperthermic Intraperitoneal Chemotherapy. It's sometimes called "hot chemotherapy." But the name can be misleading â HIPEC isn't just chemotherapy. It's actually a two-part procedure.
Part 1 is cytoreductive surgery (CRS). The surgeon removes every visible tumour deposit from the inner lining of the abdomen. This step can take anywhere from 4 to 10 hours depending on how much disease is present. It requires a highly skilled peritoneal oncology surgeon.
Part 2 is the HIPEC itself. Once the abdomen is cleared of all visible tumours, the surgical team fills the abdominal cavity with a heated chemotherapy solution â typically heated to 41â43°C â and circulates it continuously for 60 to 90 minutes. Then it's drained out, and the abdomen is closed.
Together, Part 1 and Part 2 target both the visible disease and the microscopic cancer cells too small to remove surgically. That combination is what makes HIPEC so powerful.
How HIPEC surgery works â two-part procedure: cytoreductive surgery then heated intraperitoneal chemotherapy
Heat is what makes HIPEC work differently from standard IV chemotherapy. When chemo is given intravenously, it travels through the blood to reach cancer cells â but the peritoneum actually acts as a barrier that prevents high drug concentrations from reaching tumours in the abdominal lining. IV chemotherapy, therefore, often fails to control peritoneal spread effectively.
HIPEC solves this in three ways. First, it delivers the drug directly into the abdominal cavity â no blood barrier in the way. Second, heat increases the penetration of chemotherapy into tumour tissue at the cellular level. Third, the local dose is many times higher than what could safely be given intravenously, yet systemic side effects remain much lower because the drug stays localised.
According to published data on PubMed, the combination of hyperthermia and direct peritoneal delivery results in cancer cell death that neither surgery nor IV chemo can achieve alone.
This is one of the questions we hear most often at MediGoCare. The honest answer is â it depends on your eligibility.
| Factor | HIPEC (CRS + Heated Chemo) | Palliative Chemotherapy (IV) |
|---|---|---|
| Goal | Curative or long-term disease control | Symptom management, life extension |
| 5-Year Survival (Ovarian) | 35â55% | 15â20% |
| Suitable Patients | PCI under 20, no distant spread | Any stage, including ineligible for surgery |
| Side Effects | Significant (surgical + chemo) | Systemic (fatigue, nausea, hair loss) |
| India Cost | $10,000â$22,000 | $2,000â$8,000 per year of cycles |
| Intent | Potential cure | Non-curative |
The European Society for Medical Oncology (ESMO) recommends HIPEC as a treatment option for selected patients with peritoneal metastases from colorectal cancer, and it's increasingly supported for ovarian cancer peritoneal spread as well. If you're eligible, HIPEC offers a real chance at long-term control. Palliative chemotherapy does not.
Not every cancer can be treated with HIPEC. It works specifically when cancer has spread to the peritoneal surface â the lining of the abdominal cavity â and has not spread to the lungs, liver, or other distant organs. The National Cancer Institute defines this spread as peritoneal carcinomatosis.
Below are the six core cancer types most commonly treated with HIPEC in India, followed by a section on less common but recognised emerging indications.
Ovarian cancer is the most common reason patients come to us for HIPEC. Women with Stage 3C or Stage 4A ovarian cancer â where disease is confined to the abdomen â are often excellent HIPEC candidates. Data consistently shows 35â55% five-year survival with HIPEC, compared to just 15â20% with chemotherapy alone. For gynaecological cancers more broadly, see our Cervical Cancer Treatment India page for related context.
When colorectal cancer spreads to the peritoneum, outcomes with standard chemotherapy are poor. However, HIPEC surgery changes that picture significantly for eligible patients. Studies show 30â45% five-year survival with CRS-HIPEC for colorectal peritoneal metastasis, compared to just 10â15% with systemic chemotherapy for those with a Peritoneal Cancer Index below 20. We always recommend reading our Colon Cancer Treatment India page alongside this guide.
PMP is a rare condition where a specific type of mucus-producing tumour fills the abdominal cavity. It's uncommon, which is exactly why it often gets misdiagnosed for years. The good news? HIPEC is the definitive treatment for PMP â and outcomes are remarkable. Patients with PMP see 70â85% ten-year survival when treated with CRS-HIPEC. If you've been told you have PMP, India has experienced surgeons who handle this diagnosis regularly. For blood cancers where peritoneal spread isn't the primary concern, see our Bone Marrow Transplant India â For Blood Cancers guide.
Appendix cancer very often presents alongside PMP. It's another cancer where HIPEC is now considered the standard of care at experienced centres. India's top private hospitals â particularly Fortis and Apollo â have growing appendix cancer HIPEC caseloads with surgeons experienced in managing the full spectrum of appendiceal malignancies.
Gastric cancer with peritoneal spread is more aggressive than other HIPEC indications. Results are more variable, and eligibility is evaluated much more carefully. However, data from Japanese and Korean oncology centres â where gastric cancer is more prevalent â shows a survival benefit for carefully selected patients. We discuss this option with each patient individually. If you're exploring stomach cancer options in India, also look at our Stomach Cancer Treatment India page for context on the treatment landscape.
Peritoneal mesothelioma is rare â but when it does occur, HIPEC is the primary treatment approach. Patients searching for this diagnosis have extremely high intent and genuine need for accurate information. We've supported patients with peritoneal mesothelioma from the UK and Gulf states specifically.
Beyond the six core indications above, HIPEC is being explored and used in select, carefully chosen cases for additional cancer types. These are less common, case-selected, and available only at specialised peritoneal oncology centres. They are not standard-of-care indications but are recognised by experienced HIPEC teams globally.
The cancers listed below are treated with HIPEC only in carefully selected patients at specialist centres. Eligibility is evaluated on a case-by-case basis. They are not routine HIPEC indications and outcomes vary significantly. Always consult a peritoneal oncology specialist for an individual assessment.
Select patients with small intestinal adenocarcinoma spreading to the peritoneum may be considered at experienced centres with strict eligibility criteria.
Certain low-grade abdominal sarcomas with peritoneal involvement may benefit from CRS-HIPEC. Highly centre-specific and evaluated individually.
In cases of endometrial cancer recurrence with isolated peritoneal spread and no distant metastasis, select patients are evaluated for HIPEC at specialist gynaecological oncology centres.
Highly selected cases of cervical cancer confined to the peritoneum â without lymphatic or distant spread â may be assessed for HIPEC at experienced centres.
Specific low-grade neuroendocrine tumours spreading to the peritoneum are treated with HIPEC in selected cases at centres with dedicated NET expertise.
DSRCT is an extremely rare and aggressive tumour; HIPEC is offered only at a handful of highly specialised centres globally, including select Indian centres with peritoneal oncology programmes.
MediGoCare can connect patients with these rare diagnoses to the appropriate Indian specialists. If your diagnosis falls outside the six core indications, send us your reports and we will advise honestly on whether Indian expertise is available for your specific situation.
One of the most common questions we receive at MediGoCare is: "Can HIPEC help with Stage 4 cancer?" This is a critical question deserving a dedicated, honest answer â because the answer is sometimes yes, but not always.
Stage 4 cancer is not a single category. What matters for HIPEC eligibility is where the disease has spread, not just that it is Stage 4. HIPEC can be curative-intent for some Stage 4 patients whose disease is confined to the peritoneum â but it is not appropriate if cancer has spread to the liver, lungs, bones, or lymph nodes beyond the abdomen.
| Cancer Type | Stage 4 Subtype That May Qualify | Key Requirement | Typical 5-Year Survival with HIPEC |
|---|---|---|---|
| Ovarian Cancer | Stage 4A (pleural effusion only) or Stage 3C with peritoneal-only disease | No parenchymal liver/lung spread; PCI <20 | 35â55% |
| Colorectal Cancer | M1c â peritoneal-only metastasis (Stage 4 by TNM) | No synchronous liver or lung metastases; PCI <20 | 30â45% |
| Appendix Cancer / PMP | Any stage with peritoneal-only spread | Complete cytoreduction achievable | 70â85% (10-year for PMP) |
| Gastric Cancer | Selected Stage 4 with peritoneal-only spread | Very low tumour burden; excellent performance status | 15â25% (select cases) |
Source: PSOGI international consensus guidelines. Individual outcomes depend on PCI, completeness of cytoreduction, and hospital volume.
The term "cure" is medically cautious in any Stage 4 discussion. What HIPEC can achieve in eligible Stage 4 patients is long-term disease control, extended survival, and in some cases complete remission. For ovarian cancer with peritoneal-only Stage 4A disease, a meaningful proportion of patients achieve long-term remission after CRS-HIPEC. For colorectal M1c (peritoneal-only metastasis), HIPEC is now considered a potential curative-intent treatment by ESMO.
The most important message: if you or your loved one has been told they have Stage 4 cancer with peritoneal spread, do not assume HIPEC is impossible before getting a specialist review. MediGoCare offers a free CT scan review specifically for this purpose.
One of the most important things a trustworthy HIPEC guide must do is tell you honestly when the surgery is not appropriate. Patient safety depends on proper selection. Understanding the exclusion criteria helps families avoid unnecessary travel and helps them ask the right questions of their doctors.
At MediGoCare, we take this section seriously. We will always give you an honest eligibility assessment â and if HIPEC is not appropriate for your situation, we will tell you clearly and explore alternatives such as PIPAC (pressurised intraperitoneal aerosol chemotherapy) or other systemic treatment options available in India.
Cost is usually one of the first things families ask about. And India offers something no other country can match for HIPEC â world-class surgical skill at a fraction of Western prices. All figures below are for private hospitals only, which is where MediGoCare exclusively coordinates care for international patients.
How much does HIPEC surgery cost in India vs USA? 2026 private hospital price comparison
| Hospital | City | Approx Cost (âı) | Approx Cost (USD) | USA Equivalent | Saving |
|---|---|---|---|---|---|
| Fortis Hospital Priority 1 | Gurugram / Delhi | âı9â14 lakh | $11,000â$17,000 | $90,000â$120,000 | 83â87% |
| Apollo Hospital Priority 2 | Delhi / Chennai / Hyderabad | âı10â15 lakh | $12,000â$18,000 | $90,000â$120,000 | 83â87% |
| Max Hospital Priority 3 | New Delhi (Saket / Shalimar Bagh) | âı10â14 lakh | $12,000â$17,000 | $90,000â$120,000 | 83â86% |
| Artemis Hospital | Gurugram | âı9â13 lakh | $11,000â$16,000 | $90,000â$120,000 | 83â87% |
| Sarvodaya Hospital | Faridabad / NCR | âı8â12 lakh | $9,500â$14,500 | $90,000â$120,000 | 84â89% |
| Manipal Hospital | Bengaluru / Delhi | âı10â15 lakh | $12,000â$18,000 | $90,000â$120,000 | 83â87% |
| MGM Hospital | Mumbai / Navi Mumbai | âı9â13 lakh | $11,000â$16,000 | $90,000â$120,000 | 83â87% |
| Kokilaben Hospital | Mumbai | âı10â16 lakh | $12,000â$19,000 | $90,000â$120,000 | 82â86% |
| Aster Hospital | Kerala / Bengaluru / Hyderabad | âı9â14 lakh | $11,000â$17,000 | $90,000â$120,000 | 83â87% |
âı8 lakh â âı18 lakh ($10,000 â $22,000 USD) â MediGoCare works exclusively with accredited private hospitals. Hospital selection is matched to your cancer type, PCI score, and location preferences.
For full cancer treatment cost comparisons across all types, see our Cancer Treatment Costs India â Full Breakdown.
The HIPEC package at top Indian private hospitals generally includes: cytoreductive surgery (surgical team fees, OR time), heated chemotherapy drugs (Mitomycin C, Cisplatin, or Oxaliplatin), general anaesthesia and anaesthetist fees, ICU stay (typically 3â5 days), ward admission for the remaining recovery (total stay: 10â21 days), post-operative nursing and monitoring, and standard post-op imaging before discharge.
It typically excludes: accommodation outside the hospital for your caregiver, pre-operative evaluation done in your home country, follow-up CT scans after returning home, and flights. MediGoCare helps you plan all of this transparently â no hidden surprises.
Survival data is what most patients and families care about most. Here's what the published literature â including sources on PubMed â shows for HIPEC outcomes by cancer type.
HIPEC survival rates by cancer type â ovarian, colorectal, pseudomyxoma peritonei outcomes India 2026
| Disease | 5-Year Survival With HIPEC | 5-Year Survival Without HIPEC | Evidence Level |
|---|---|---|---|
| Ovarian Cancer (Peritoneal) | 35â55% | 15â20% | High (RCT data) |
| Colorectal Peritoneal Metastasis | 30â45% | 10â15% | High (multiple studies) |
| Pseudomyxoma Peritonei | 70â85% (10-year) | Poor without CRS | Very High |
| Appendix Cancer | 50â70% | 20â30% | Moderate |
| Gastric Cancer (Peritoneal) | 15â25% (select cases) | 5â10% | Moderate |
| Peritoneal Mesothelioma | 40â60% | 10â20% | Moderate |
These figures come from international data, and India's outcomes at high-volume private centres are comparable. Surgeons at Fortis, Apollo, and Max Healthcare publish outcomes that align with global benchmarks. Moreover, the Peritoneal Surface Oncology Group International (PSOGI) â the defining professional body for HIPEC globally â recognises India as an emerging hub for peritoneal oncology.
One thing we always tell patients at MediGoCare: survival statistics are population averages. Your individual outcome depends on your PCI score, your general health, and the experience of your surgical team. That's why choosing the right hospital and surgeon matters enormously â and it's exactly what we help you do.
Not everyone with abdominal cancer is suitable for HIPEC. The selection process is strict â and that's a good thing. Surgery on the wrong patient can cause harm without benefit. Broadly, a HIPEC candidate must have: peritoneal spread confined to the abdomen, a Peritoneal Cancer Index (PCI) under 20, no spread to the liver, lungs, or other distant organs, and good overall fitness (ECOG performance status 0 or 1).
There's no strict age cut-off. We've seen successful HIPEC surgeries in patients aged 30 to 74. But overall fitness matters more than age numbers.
How is PCI score calculated for HIPEC eligibility? Abdominal regions mapped for peritoneal cancer index
Your CT scan or PET-CT report is the starting point for estimating PCI. That's why we always ask international patients to send us their imaging first. We then have our peritoneal oncology specialists review it before we recommend any next steps. It's free, and it saves you from flying to India only to be told you're not a candidate.
As PSOGI guidelines define, complete cytoreduction â removing all visible disease â is the most critical predictor of long-term survival.
Send us your CT scan report and we'll review your eligibility within 48 hours â at no charge. Our peritoneal oncology specialist partners will give you an honest assessment.
Recovery from HIPEC is significant. This is a major abdominal surgery and patients need to plan their time in India accordingly. Here's a realistic picture.
In the hospital (10â21 days): The first 3â5 days are usually in ICU. Pain is managed with strong medications and an epidural catheter in most cases. Most patients describe the first week as uncomfortable but manageable. By day 5â7, pain typically reduces significantly and patients start walking with assistance.
Diet after HIPEC: First 1â2 weeks: liquid diet only. Weeks 3â4: soft foods introduced gradually. Week 6 onwards: returning to near-normal diet.
Full recovery timeline: Most patients feel functionally well at 6â8 weeks. But complete internal healing takes 3â4 months. Light activities can resume at 4â6 weeks.
Follow-up scans: CT scan at 3 months post-surgery (most important), CT scan at 6 months, then annual CT scans thereafter.
Fit to fly: Most patients are cleared to fly home approximately 4â6 weeks after surgery, subject to their surgeon's assessment. Long-haul flights over 8 hours may require one extra week of recovery. MediGoCare arranges the formal Fit-to-Fly certificate from your treating hospital before discharge planning â so your airline and insurance are covered.
India has several private hospitals with dedicated peritoneal oncology departments. MediGoCare works exclusively with accredited private hospitals. Here is a summary of the centres we work with, listed in order of priority for international patient referrals.
| Hospital | City / Network | HIPEC Capability | Accreditation | Key Strength |
|---|---|---|---|---|
| Fortis Hospital | Gurugram, Delhi, Mumbai, Chennai | Full CRS-HIPEC programme | NABH + JCI | Pan-India network; strong surgical oncology teams; robotic capability |
| Apollo Hospital | Delhi, Chennai, Hyderabad, Kolkata | Full CRS-HIPEC programme | JCI + NABH | Multilingual international patient support; largest pan-India private network |
| Max Hospital | New Delhi (Saket, Shalimar Bagh, Vaishali) | Full CRS-HIPEC programme | NABH | Strong gynaecological oncology for ovarian HIPEC; advanced ICU care |
| Artemis Hospital | Gurugram | CRS-HIPEC programme | NABH + JCI | Proximity to Delhi airport; focused oncology unit |
| Sarvodaya Hospital | Faridabad (Delhi NCR) | HIPEC available | NABH | Cost-effective private option in NCR; growing oncology department |
| Manipal Hospital | Bengaluru, Delhi, Mangalore | Full CRS-HIPEC programme | NABH + JCI | South India hub; excellent gynaecological and colorectal oncology teams |
| MGM Hospital | Mumbai / Navi Mumbai | HIPEC available | NABH | Mumbai-based; growing peritoneal oncology capability |
| Kokilaben Hospital | Mumbai | Full CRS-HIPEC programme | NABH + JCI | Premier Mumbai centre; advanced cancer surgery and dedicated oncology floors |
| Aster Hospital | Kerala, Bengaluru, Hyderabad | HIPEC available | NABH | Strong Gulf patient network; Kerala is a major hub for patients from the Middle East |
MediGoCare has direct relationships with the peritoneal oncology teams at all nine of these hospitals. We don't just recommend â we match. Your cancer type, PCI, travel logistics, and budget all influence which hospital is right for you. Many of these centres also offer robotic cancer surgery in India for select cases alongside their HIPEC programmes.
According to Cancer Research UK, UK patients travelling abroad for complex cancer surgery should prioritise hospitals with established peritoneal oncology units and documented surgical volumes â which all nine hospitals above meet.
We handle every step so you can focus on one thing â getting better.
Share your most recent CT scan or PET-CT report via WhatsApp, email, or our website form. It's completely free.
Our oncology team reviews your imaging with a peritoneal oncology specialist and advises you on HIPEC candidacy â including honest guidance if HIPEC is not appropriate.
We provide 2â3 private hospital options with surgeon profiles and detailed cost estimates. No obligation.
MediGoCare provides the hospital invitation letter needed for your India e-Medical Visa. Approval typically takes 3â5 business days.
We arrange airport transfer, hospital pre-admission, interpreter if needed, and nearby accommodation for your caregiver.
Fly home with your Fit-to-Fly certificate, discharge summary, and MediGoCare's remote follow-up coordination.
Patients from the UK, Nigeria, Bangladesh, Oman, and across the Gulf states have all completed their HIPEC journeys through MediGoCare. We understand what makes each country's patient journey different â from visa requirements to dietary needs to follow-up communication back home.
Yes. HIPEC surgery is available for international patients at leading Indian private hospitals including Fortis, Apollo, Max Healthcare, Artemis, Sarvodaya, Manipal, MGM, Kokilaben, and Aster. These centres have dedicated peritoneal oncology departments with surgeons experienced in both cytoreductive surgery and HIPEC. MediGoCare coordinates the full journey for international patients.
HIPEC surgery in India costs approximately âı8 lakh to âı18 lakh â that's $10,000â$22,000 USD â at top private hospitals. This includes the cytoreductive surgery, heated chemotherapy, ICU stay, and a 10â21 day hospital admission. By comparison, HIPEC surgery costs $90,000â$120,000 in the USA. India offers roughly an 85% cost saving without compromising on surgical quality.
Sometimes yes. HIPEC can be a curative-intent treatment for Stage 4 patients whose cancer is confined to the peritoneum (abdominal lining) with no liver, lung, or distant spread, and a PCI score below 20. This includes select Stage 4A ovarian cancer patients and colorectal M1c (peritoneal-only) patients. HIPEC is not appropriate if cancer has spread to the liver, lungs, bones, or lymph nodes beyond the abdomen. Send your CT scan for a free eligibility assessment.
HIPEC is not recommended for patients with extensive liver metastasis, lung metastasis, a very high PCI score (above 20â25), poor performance status (ECOG 2 or higher), severe malnutrition, multiple prior failed abdominal surgeries, or significant uncontrolled comorbidities. Proper patient selection is critical to both safety and survival benefit. MediGoCare will always tell you honestly if HIPEC is not appropriate for your case.
HIPEC is performed under general anaesthesia, so patients feel no pain during the procedure itself. After surgery, patients receive strong pain management in ICU â usually an epidural plus IV pain relief. Most patients find the discomfort manageable and significantly reduced by day 5â7. Some soreness is normal for 3â4 weeks during recovery, but it gradually improves week by week.
HIPEC surgery at Indian private hospitals can typically be scheduled within 2â4 weeks of initial consultation, subject to surgical team availability and pre-operative workup. This is significantly faster than most Western countries, where waiting times for complex cancer surgery regularly stretch to 3â6 months. For patients with time-sensitive disease, India's shorter waiting time is often medically significant.
Most HIPEC patients are cleared to fly home approximately 4â6 weeks after surgery. MediGoCare arranges a formal Fit-to-Fly certificate from the treating hospital before discharge planning. Long-haul flights over 8 hours may require one additional week of recovery. We also advise whether a medical escort is needed for your specific route.
The most commonly used drugs for HIPEC in India are Mitomycin C (for colorectal and appendix cancers) and Cisplatin (for ovarian cancer and mesothelioma). Some centres now use Oxaliplatin for colorectal peritoneal metastases based on updated protocols. The drug choice depends on your tumour type and your surgeon's protocol, and is specified during pre-operative planning.
The PCI is a scoring system that measures how much cancer is spread across 13 regions of the abdomen, on a scale of 0 to 39. A PCI under 20 is generally required for HIPEC eligibility. The lower the PCI, the better the expected outcome. Surgeons estimate your PCI from your CT scan before recommending surgery. PSOGI â the international peritoneal oncology body â defines PCI under 20 as the standard eligibility cut-off.
Yes. Alternatives include systemic (IV) chemotherapy and PIPAC (pressurised intraperitoneal aerosol chemotherapy) â a newer and less invasive approach for patients not eligible for full HIPEC. PIPAC is now available at select Indian centres and may be appropriate for patients with higher PCI scores or reduced fitness. MediGoCare can help you explore all options based on your specific diagnosis.
It starts with one step: send us your CT scan report. Email it to info@medigocare.com, share it on WhatsApp at +91 90858 83067, or fill in the form on our website at medigocare.com. Within 48 hours, our team will review your imaging with a peritoneal oncology specialist and give you an honest assessment. There's no charge for this first step.
Send your CT scan today for a free, honest eligibility assessment from our peritoneal oncology specialists. No obligation. Response within 48 hours.
24/7 Assistance with the best medical care at your service
Quality treatment with professional & unmatched personal care
Our experts make your Communication easier and more transparent